NCT03168412View on ClinicalTrials.gov

A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)

PHASE4CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

July 15, 2018

Study Completion Date

November 28, 2018

Conditions
Hepatitis E
Interventions
BIOLOGICAL

Recombinant Hepatitis E Vaccine (Escherichia Coli)

Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.

BIOLOGICAL

Recombinant Hepatitis E Vaccine (Escherichia Coli)

Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Trial Locations (1)

324200

Changshan Center for Disease Control and Prevention, Quzhou

All Listed Sponsors
lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

NCT03168412 - A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule) | Biotech Hunter | Biotech Hunter